Company record · updated August 5, 2026
Blue Marlin Therapeutics Stock: 4 valuation observations from SEC filings
Every row below names the filing it came from. Coverage for this company runs December 31, 2025 to March 31, 2026.
4observations
4source filings
4verified rows
2026-03-31most recent as-of date
Source rails for this company: N-PORT fund mark (4).
Reported by 2 filers: T. Rowe Price Health Sciences Fund, Inc., T. Rowe Price Health Sciences Portfolio.
| As of | Measure | Value | Reported by | Tier | What the filing says | Accession |
|---|---|---|---|---|---|---|
| 2026-03-31 | price per share | 0.1 USD | T. Rowe Price Health Sciences Portfolio | VERIFIED | valUSD 8.1 / balance 81.0 [common / pp] | 000109926326006593 |
| 2026-03-31 | price per share | 0.1 USD | T. Rowe Price Health Sciences Fund, Inc. | VERIFIED | valUSD 180.3 / balance 1803.0 [common / pp] | 000109926326006598 |
| 2025-12-31 | price per share | 0.1 USD | T. Rowe Price Health Sciences Portfolio | VERIFIED | valUSD 8.1 / balance 81.0 [common / pp] | 000109926326002544 |
| 2025-12-31 | price per share | 0.1 USD | T. Rowe Price Health Sciences Fund, Inc. | VERIFIED | valUSD 180.3 / balance 1803.0 [common / pp] | 000109926326002549 |
Reading these figures
A fund mark is the filer's own fair-value estimate at a quarter end, not a transaction price, and two filers can reach different values for the same date. A charter round price is the issue price of that series at issuance. Neither is a current market price. The capabilities page states the full limits.